泻白散与苇茎汤治疗肺炎初期的效果分析

A clinical analysis of treating early Pneumonia with Xiebai San and Weijing decoction

目的:利用临床观察的方法,评价泻白散和苇茎汤治疗肺炎的疗效和安全性。方法:将150例肺炎患者随机分成2组。实验组采用泻白散治疗75例,对照组采用苇茎汤治疗75例。经过2周的治疗疗程,观察疗效。通过两独立样本t检验的统计学方法,对两组的疗效进行统计学分析。结果:在150例患者中,泻白散治疗组有效率93.80%,苇茎汤治疗组的有效率为85.61%。经两独立样本t检验两两比较,泻白散治疗组的有效率均高于单独用苇茎汤组,P值为0.003(<0.05)。在两组治疗过程中,患者均未出现严重不良反应,1周后,均对两组患者拍摄X光片,发现胸部X片无肺纹理增粗及炎症表现,血液常规检测,发现血细胞均无显著性变化,与正常血液分析比较差异无统计学意义(P>0.05)。结论:泻白散治疗肺炎的效果明显好于单独服用苇茎汤的有效率。同时,在采取两种不同治疗方法的治疗过程中,均无出现严重的不良反应和肝功能受损的情况。

Objective： To evaluate clinical efficacy and safety of Xiebai San and Weijing decoction. Methods： 150 cases of pneumonia were randomly divided into two groups. The experimental group accept Xiebai San in 75;in the control group 75 cases took the Weijing decoction. Through two independent samples t test statistical methods , the efficacy of the two groups were statistically analyzed.＆amp;nbsp;Results： The treatment group had efficiency of Xiebai San for 93.80%, in Weijing Decoction group was 85.61% effective. After two independent sample t test comparison , the effective rate of Xiebai than Weijing decoction group , P value of 0.003 （P〈0.05） . There were no serious adverse reactions. Conclusion：Xiebai San in treating pneumonia was significantly better than taking a single Weijing decoction. Meanwhile, no serious adverse reactions occur.